Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%) / Bausch Health 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%) / Bausch Health
    Enrollment open, Trial completion date, Trial primary completion date:  Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus (clinicaltrials.gov) -  Feb 12, 2021   
    P1,  N=20, Enrolling by invitation, 
    Unknown status --> Completed | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021 Not yet recruiting --> Enrolling by invitation | Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021
  • ||||||||||  Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%) / Bausch Health
    [VIRTUAL] A Case of Enucleation Following Poorly Controlled Ocular Surface Disease Status Post Dacryoadenectomy (Track 1 - Academy at Home) -  Oct 14, 2020 - Abstract #AAOPT2020AAOPT_672;    
    Amniotic membranes and scleral lenses may also delay the need for enucleation and should have been considered along with prophylactic antivirals given the prior HSK and steroid use.2,3 Conclusion There are a variety of options disposable to treat DED, but the underlying cause should be considered in order to tailor treatment accordingly. This case demonstrates the serious consequences that can arise from poorly controlled OSD due to dacryoadenectomy, and the need for aggressive therapeutic intervention.
  • ||||||||||  loteprednol etabonate / Generic mfg.
    PK/PD data, Journal:  Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38. (Pubmed Central) -  Sep 24, 2020   
    This case demonstrates the serious consequences that can arise from poorly controlled OSD due to dacryoadenectomy, and the need for aggressive therapeutic intervention. LE (submicron) gel 0.38% demonstrated similar rheological properties to micronized LE gel 0.5% but faster dissolution, thus providing similar or higher LE concentrations in the aqueous humor, cornea, and iris-ciliary body after ocular dosing in rabbits despite a lowered concentration of drug in the formulation.